Emerging therapies in the pharmacological treatment of Parkinson's disease

Drugs
Amos D Korczyn, Miri Nussbaum

Abstract

The pharmacological management of Parkinson's disease is a complex and dynamic task; there is no one 'right' strategy indicating which drugs should be used at a particular stage of the disease. There are now many different drugs belonging to several classes that may be effective, and there are still differences of opinion among leading clinicians about the best course of treatment. This review focuses on drug therapy for the motor impairment in Parkinson's disease. Current and future research directions are summarised by taking inventory of recent and innovative areas of development in the field, representing each category with at least one of its featured treatments. The main research efforts are being directed towards delaying the use of levodopa or finding therapies to be used as adjunct to it, in order to postpone motor complications and, in particular, dyskinesias. One of the recent trends is early employment of dopamine agonists. Additional efforts are being directed towards protecting and restoring dopamine neurons. Novel therapies acting on non-dopaminergic systems are also being researched.

References

Jan 1, 1979·Journal of Neural Transmission·Y Eshel, A D Korczyn
Jun 1, 1978·The American Journal of Psychiatry·C MoskovitzH L Klawans
Jan 1, 1992·Movement Disorders : Official Journal of the Movement Disorder Society·M R LuquinJ A Obeso
Jan 1, 1992·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·J M RabeyA D Korczyn
Jan 1, 1992·Movement Disorders : Official Journal of the Movement Disorder Society·M A MenaJ García de Yébenes
Sep 1, 1972·Neuropharmacology·A D Korczyn
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·U K Rinne
Mar 1, 1995·The Annals of Pharmacotherapy·D L CorboyJ I Sage
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Aug 1, 1995·Clinical Neuropharmacology·J P HubbleA Elvin
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·T G HastingsM J Zigmond
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·J P SteinerP D Suzdak
Aug 1, 1997·Current Opinion in Neurology·D J Brooks
Jun 13, 1998·The Journal of Pharmacy and Pharmacology·H Seager
May 29, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·S A Factor, E S Molho
Jun 9, 1999·Annals of Neurology·O RascolJ G Nutt
Aug 6, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·W OndoJ Jankovic
Sep 24, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·J L MontastrucJ M Senard
Dec 3, 1999·Progress in Neuro-psychopharmacology & Biological Psychiatry·E BezardC E Gross
Dec 10, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·Y AgidE Tolosa
Feb 11, 2000·Annals of the New York Academy of Sciences·M P Abbracchio, F Cattabeni

❮ Previous
Next ❯

Citations

Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jerry J Buccafusco
Aug 14, 2003·Parkinsonism & Related Disorders·Fabrizio Stocchi
Feb 14, 2012·Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)·David B Elliott
Mar 26, 2014·Journal of Medicinal Chemistry·Tesfaye BiftuAnn E Weber
Sep 6, 2011·Parkinsonism & Related Disorders·Sophie DrapierMarc Vérin
Feb 4, 2010·Parkinsonism & Related Disorders·Fabrizio Stocchi
Feb 24, 2009·Archivos de bronconeumología·Manuel Haro-EstarriolSalvi Sendra-Salillas
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Fabrizio StocchiC Warren Olanow
Jul 11, 2006·Journal of the Neurological Sciences·L ElmerUNKNOWN PRESTO Investigators
Nov 1, 2002·Expert Review of Neurotherapeutics·Fabrizio Stocchi
Oct 8, 2005·The Journal of Biological Chemistry·Hai-Ying ShenJiang-Fan Chen
Jan 20, 2007·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·Kunji ShirahamaRyuji Kobayashi
Apr 29, 2015·The British Journal of Dermatology·E Ormerod, D de Berker
Feb 20, 2018·Journal of Neurosciences in Rural Practice·Dushyanth Babu JastiA Mohan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.